| Animal models of hepatocellular carcinoma: the role of immune system and tumor microenvironment Z Macek Jilkova, K Kurma, T Decaens Cancers 11 (10), 1487, 2019 | 58 | 2019 |
| Immunologic features of patients with advanced hepatocellular carcinoma before and during sorafenib or anti-programmed death-1/programmed death-L1 treatment ZM Jilkova, C Aspord, K Kurma, A Granon, C Sengel, N Sturm, PN Marche, ... Clinical and translational gastroenterology 10 (7), 2019 | 43 | 2019 |
| Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma ZM Jilkova, AZ Kuyucu, K Kurma, STA Pour, GS Roth, G Abbadessa, Y Yu, ... Oncotarget 9 (13), 11145, 2018 | 38 | 2018 |
| DEN-induced rat model reproduces key features of human hepatocellular carcinoma K Kurma, O Manches, F Chuffart, N Sturm, K Gharzeddine, J Zhang, ... Cancers 13 (19), 4981, 2021 | 35 | 2021 |
| Efficacy of AKT inhibitor ARQ 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinoma GS Roth, Z Macek Jilkova, A Zeybek Kuyucu, K Kurma, ST Ahmad Pour, ... Molecular Cancer Therapeutics 16 (10), 2157-2165, 2017 | 26 | 2017 |
| Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target? K Kurma, A Boizard-Moracchini, G Galli, M Jean, P Vacher, P Blanco, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876 (2), 188596, 2021 | 12 | 2021 |
| GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition E Bestion, ZM Jilkova, JL Mège, M Novello, K Kurma, STA Pour, ... Therapeutic Advances in Chronic Disease 11, 2040622320942042, 2020 | 12 | 2020 |
| Chronic intermittent hypoxia increases cell proliferation in hepatocellular carcinoma L Carreres, M Mercey-Ressejac, K Kurma, J Ghelfi, C Fournier, ... Cells 11 (13), 2051, 2022 | 9 | 2022 |
| Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model K Kurma, A Zeybek Kuyucu, GS Roth, N Sturm, M Mercey-Ressejac, ... International Journal of Molecular Sciences 23 (24), 16206, 2022 | 5 | 2022 |
| Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype K Kurma, C Alix-Panabières Frontiers in Cell and Developmental Biology 11, 1188499, 2023 | 4 | 2023 |
| Clinical and experimental evaluation of diagnostic significance of alpha-fetoprotein and osteopontin at the early stage of hepatocellular cancer Z Macek-Jilkova, SI Malov, K Kurma, C Charrat, T Decaens, ... Bulletin of Experimental Biology and Medicine 170, 340-344, 2021 | 4 | 2021 |
| MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways SF Kenji, K Kurma, B Collet, C Oblet, L Debure, C Di Primo, L Minder, ... Cell Death & Disease 13 (10), 895, 2022 | 2 | 2022 |
| DEN-induced rat model reproduces key features of human hepatocellular carcinoma. Cancers 2021; 13: 4981 K Kurma, O Manches, F Chuffart, N Sturm, K Gharzeddine, J Zhang, ... s Note: MDPI stays neu-tral with regard to jurisdictional claims in …, 2021 | 2 | 2021 |
| In vitro cross-talk between metastasis-competent circulating tumor cells and platelets in colon cancer: a malicious association during the harsh journey in the blood Z Eslami-S, LE Cortés-Hernández, I Glogovitis, M Antunes-Ferreira, ... Frontiers in cell and developmental biology 11, 1209846, 2023 | 1 | 2023 |
| First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study T Bardol, Z Eslami‐S, D Masmoudi, M Alexandre, M Duboys de Labarre, ... Cancer Medicine 13 (1), e6843, 2024 | | 2024 |
| CD95L concatemers highlight different stoichiometries of CD95‐mediated apoptotic and nonapoptotic pathways E Lebrault, C Oblet, K Kurma, N Levoin, R Jeannet, M Jean, P Vacher, ... European Journal of Immunology, 2350626, 2023 | | 2023 |
| CD95L concatemers highlight difference in the manner CD95-mediated apoptotic and non-apoptotic pathways are triggered. E Lebrault, C Oblet, K Kurma, N Levoin, M Jean, P Vacher, P Legembre bioRxiv, 2023.06. 22.546070, 2023 | | 2023 |
| Modèle animal de carcinome hépatocellulaire sur foie cirrhotique: description et utilisation pour essais thérapeutiques pré-cliniques K Kurma Université Grenoble Alpes (ComUE), 2019 | | 2019 |
| Animal model of cirrhosis with hepatocellular carcinoma: a reliable tool for testing new therapies. K Kurma Université Grenoble Alpes, 2019 | | 2019 |
| GNS561 a new quinoline derivative inhibits the growth of hepatocellular carcinoma in a cirrhotic rat and human PDX orthotopic mouse models F Bassissi, ZM Jilkova, S Brun, J Courcambeck, J Tracz, K Kurma, ... Cancer Research 77 (13_Supplement), 5124-5124, 2017 | | 2017 |
